Top Markets
#1 MowCat MowCat +365.09%
#2 Islamic Coin Islamic Coin +152.17%
#3 龙虾 (Lobster) 龙虾 (Lobster) +61.81%
#4 SODAX SODAX +54.53%
#5 Cortex Cortex +31.73%
#6 DexNet DexNet +23.20%
#7 BNB Attestation Service BNB Attestation Service +20.89%
#8 Pons Pons +20.05%
#9 Akedo Akedo +18.91%
#10 OpenEden OpenEden +18.09%
Coin of the day
MowCat MowCat
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Classement en actions #7142
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Prix de l'action
$40.39
Dernière synchronisation: 2023-08-18
Capitalisation boursière
$1.70B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Chinook Therapeutics, Inc. (KDNY)

Catégorie

Healthcare
Ratio P/B pour Chinook Therapeutics, Inc. (KDNY)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Chinook Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Chinook Therapeutics, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH